Fibrogen Inc share price today

(FGEN)

Fibrogen Inc share price is $0.41 & ₹34.73

$0.41

▲

-0.01

(-2.57%)

Market is closed - opens 8 PM, 04 Dec 2024

View live Fibrogen Inc share price in Dollar and Rupees. Guide to invest in Fibrogen Inc from India. Also see the sentimental analysis on Indian investors investing in Fibrogen Inc. Get details on the Indian mutual funds that are investing in Fibrogen Inc. Get Analyst recommendations and forecasts along with all the Fibrogen Inc's financials.

Fibrogen Inc share price movements

$0.40
$0.43
$0.41
1.24%
Downside
Day's Volatility :5.38%
Upside
4.18%
$0.18
$2.93
$0.41
56.1%
Downside
52 Weeks Volatility :93.86%
Upside
86.01%

Fibrogen Inc Returns

Period	Fibrogen Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	5.36%	-6.1%	0.0%
6 Months	-65.21%	1.4%	0.0%
1 Year	-24.1%	11.4%	0.0%
3 Years	-97.03%	12.9%	-18.1%

Fibrogen Inc Key Statistics

in dollars & INR

Market Capitalization	$42.8M
Revenue TTM	$173.8M
EBITDA	$-165.8M
Earnings Per Share (EPS)	$-1.23
Profit Margin	-96.84%
Quarterly Earnings Growth YOY	0.54%
Return On Equity TTM	-1015.79%

How to invest in Fibrogen Inc from India?

It is very easy for Indian residents to invest directly in Fibrogen Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Fibrogen Inc stock in both rupees (INR) and dollars (USD). Search for Fibrogen Inc or FGEN on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Fibrogen Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Fibrogen Inc shares which would translate to 2.066 fractional shares of Fibrogen Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Fibrogen Inc

140%

Period: Sep 4, 2024 to Dec 3, 2024. Change in 30 Days versus previous period

Search volume for Fibrogen Inc on INDmoney from India has grown in the last 30 days as on Dec 4, 2024. 140% more investors are searching Fibrogen Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Fibrogen Inc

PRIMECAP Management Company
9.84%
Armistice Capital, LLC
6.75%
Vanguard Group Inc
5.84%
BlackRock Inc
2.39%
683 Capital Management LLC
2.12%
Jacobs Levy Equity Management, Inc.
2.09%

Analyst Recommendation on Fibrogen Inc

Sell

0%Buy

37%Hold

62%Sell

Based on 8 Wall street analysts offering stock ratings for Fibrogen Inc(by analysts ranked 0 to 5 stars)

Based on 8 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Fibrogen Inc

What analysts predicted

Upside of 46.34%

Current:

$0.41

Target:

$0.60

Insights on Fibrogen Inc

Decreasing Revenue
Revenue is down for the last 3 quarters, 55.90M → 46.33M (in $), with an average decrease of 9.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -15.54M → -17.08M (in $), with an average decrease of 9.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 46.4% return, outperforming this stock by 81.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 144.5%

Fibrogen Inc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$213.0M	↑ 69.46%
Net Income	$-86.4M	↓ 31.52%
Net Profit Margin	-40.58%	↑ 59.85%

	FY19	Y/Y Change
Revenue	$256.6M	↑ 20.48%
Net Income	$-77.0M	↓ 10.93%
Net Profit Margin	-30.0%	↑ 10.58%

	FY20	Y/Y Change
Revenue	$176.3M	↓ 31.28%
Net Income	$-189.3M	↑ 145.93%
Net Profit Margin	-107.36%	↓ 77.36%

	FY21	Y/Y Change
Revenue	$235.3M	↑ 33.46%
Net Income	$-291.0M	↑ 53.75%
Net Profit Margin	-123.68%	↓ 16.32%

	FY22	Y/Y Change
Revenue	$140.7M	↓ 40.19%
Net Income	$-295.2M	↑ 1.44%
Net Profit Margin	-209.78%	↓ 86.1%

	FY23	Y/Y Change
Revenue	$147.8M	↑ 4.99%
Net Income	$-284.2M	↓ 3.72%
Net Profit Margin	-192.37%	↑ 17.41%

	Q2 FY23	Q/Q Change
Revenue	$44.3M	↑ 22.56%
Net Income	$-87.7M	↑ 13.13%
Net Profit Margin	-197.84%	↑ 16.48%

	Q3 FY23	Q/Q Change
Revenue	$40.1M	↓ 9.44%
Net Income	$-63.6M	↓ 27.45%
Net Profit Margin	-158.51%	↑ 39.33%

	Q4 FY23	Q/Q Change
Revenue	$27.1M	↓ 32.38%
Net Income	$-56.2M	↓ 11.61%
Net Profit Margin	-207.21%	↓ 48.7%

	Q1 FY24	Q/Q Change
Revenue	$55.9M	↑ 105.99%
Net Income	$-32.9M	↓ 41.43%
Net Profit Margin	-58.91%	↑ 148.3%

	Q2 FY24	Q/Q Change
Revenue	$50.6M	↓ 9.41%
Net Income	$-15.5M	↓ 52.8%
Net Profit Margin	-30.69%	↑ 28.22%

	Q3 FY24	Q/Q Change
Revenue	$46.3M	↓ 8.51%
Net Income	$-17.1M	↑ 9.91%
Net Profit Margin	-36.87%	↓ 6.18%

	FY18	Y/Y Change
Total Assets	$880.6M	↓ 2.01%
Total Liabilities	$352.1M	↑ 11.36%

	FY19	Y/Y Change
Total Assets	$857.4M	↓ 2.63%
Total Liabilities	$322.0M	↓ 8.56%

	FY20	Y/Y Change
Total Assets	$826.8M	↓ 3.56%
Total Liabilities	$385.4M	↑ 19.69%

	FY21	Y/Y Change
Total Assets	$773.8M	↓ 6.41%
Total Liabilities	$544.7M	↑ 41.34%

	FY22	Y/Y Change
Total Assets	$610.1M	↓ 21.16%
Total Liabilities	$611.6M	↑ 12.27%

	FY23	Y/Y Change
Total Assets	$423.5M	↓ 30.58%
Total Liabilities	$585.7M	↓ 4.23%

	Q2 FY23	Q/Q Change
Total Assets	$515.1M	↓ 4.35%
Total Liabilities	$575.4M	↑ 1.41%

	Q3 FY23	Q/Q Change
Total Assets	$460.4M	↓ 10.62%
Total Liabilities	$575.6M	↑ 0.03%

	Q4 FY23	Q/Q Change
Total Assets	$423.5M	↓ 8.01%
Total Liabilities	$585.7M	↑ 1.75%

	Q1 FY24	Q/Q Change
Total Assets	$365.9M	↓ 13.61%
Total Liabilities	$552.0M	↓ 5.75%

	Q2 FY24	Q/Q Change
Total Assets	$293.2M	↓ 19.86%
Total Liabilities	$483.6M	↓ 12.4%

	Q3 FY24	Q/Q Change
Total Assets	$264.4M	↓ 9.82%
Total Liabilities	$466.1M	↓ 3.61%

	FY18	Y/Y Change
Operating Cash Flow	$-76.1M	↑ 14.48%
Investing Cash Flow	$-522.1M	↓ 847.32%
Financing Cash Flow	$13.9M	↓ 97.21%

	FY19	Y/Y Change
Operating Cash Flow	$-78.7M	↑ 3.36%
Investing Cash Flow	$120.0M	↓ 122.99%
Financing Cash Flow	$-4.3M	↓ 130.99%

	FY20	Y/Y Change
Operating Cash Flow	$81.6M	↓ 203.68%
Investing Cash Flow	$452.5M	↑ 277.02%
Financing Cash Flow	$13.3M	↓ 410.3%

	FY21	Y/Y Change
Operating Cash Flow	$-82.2M	↓ 200.77%
Investing Cash Flow	$-427.0M	↓ 194.36%
Financing Cash Flow	$-563.0K	↓ 104.22%

	FY22	Y/Y Change
Operating Cash Flow	$-145.9M	↑ 77.46%
Investing Cash Flow	$89.1M	↓ 120.87%
Financing Cash Flow	$46.8M	↓ 8408.35%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-110.6M	↑ 8.84%
Investing Cash Flow	$-14.3M	↓ 113.8%
Financing Cash Flow	$91.5M	↑ 190.72%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-84.5M	↓ 23.54%
Investing Cash Flow	$54.2M	↓ 479.54%
Financing Cash Flow	$-22.0K	↓ 100.02%

Fibrogen Inc Technicals Summary

Sell

Neutral

Buy

Fibrogen Inc is currently in a neutral trading position according to technical analysis indicators.

Fibrogen Inc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Fibrogen Inc	29.38%	-65.21%	-24.1%	-97.03%	-99.11%
Regeneron Pharmaceuticals, Inc.	-8.02%	-24.21%	-7.13%	21.97%	104.79%
Biontech Se	7.55%	14.34%	18.7%	-58.12%	380.92%
Alnylam Pharmaceuticals, Inc.	-6.28%	66.39%	48.51%	42.94%	104.44%
Vertex Pharmaceuticals Incorporated	-1.5%	-3.58%	31.51%	127.12%	108.61%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Fibrogen Inc	NA	NA	0.0	-0.86	-10.16	-0.27	NA	-2.07
Regeneron Pharmaceuticals, Inc.	18.55	18.55	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.23	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Fibrogen Inc	Sell	$42.8M	-99.11%	NA	-96.84%
Regeneron Pharmaceuticals, Inc.	Buy	$83.0B	104.79%	18.55	33.61%
Biontech Se	Buy	$28.9B	380.92%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	104.44%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$120.6B	108.61%	32.84	-4.51%

About Fibrogen Inc

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.

Organization	Fibrogen Inc
Employees	486
CEO	Mr. Thane Wettig
Industry	Health Technology

Important FAQs about investing in Fibrogen Inc from India :

What is Fibrogen Inc share price today?

Fibrogen Inc (FGEN) share price today is $0.41.

Can Indians buy Fibrogen Inc shares?

Yes, Indians can invest in the Fibrogen Inc (FGEN) from India.

With INDmoney, you can buy Fibrogen Inc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Fibrogen Inc at zero transaction cost.

How can I buy Fibrogen Inc shares from India?

It is very easy to buy Fibrogen Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Fibrogen Inc be purchased?

Yes, you can buy fractional shares of Fibrogen Inc with INDmoney app.

What are the documents required to start investing in Fibrogen Inc stocks?

To start investing in Fibrogen Inc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.